Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOM trial of adjuvant tebentafusp versus observation in high-risk uveal melanoma
NL-OMON60878Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in intraocular melanoma comparing Tebentafusp with Observation (2 arms). Primary endpoint: Recurrence-free survival. Started Feb 2025; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON60878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60878.